Biotech founder and CEO Jan Jensen has never been one for following the beaten track. As a young scientist studying the formation of insulin-producing pancreatic cells, Jensen questioned the prevailing view that these cells descended from neuroectoderm. His pancreatic embryonic tissue studies told him otherwise: insulin-producing pancreatic cells originate from within the pancreas itself. Jensen’s hypothesis, now the accepted view, and his further studies made him the first developmental biologist at Novo Nordisk, at a time when the world’s largest insulin producer had little interest in cell-based therapy. Now, 20 years later, Novo Nordisk is at the forefront of cell-based Type I Diabetes research. [Read more…]
Advances in Exosome Isolation and Characterization: Technologies, Commercial Vendors, and Clinical Implications
Because exosomes are being explored for a diverse range of therapeutic applications, it is critical to optimize exosome isolation methods for maximum yield, purity, and reproducibility. Beyond the classical ultracentrifugation method, there are now several commercial exosome isolation kits developed around specific principles, such as charge neutralization-based precipitation, gel-filtration, and affinity purification using magnetic beads, that are available in the global market. [Read more…]
10 Cell Therapy Stocks That Will Be Intriguing to Watch in 2026
Cell therapy companies are those who use the building blocks of life to improve human diseases and disorders. Cell therapy involves the use of cells and tissues to regenerate, repair, and enhance human health. While our medical system has traditionally relied on drugs and surgical treatments, this trend is shifting as a expanding number of cell therapy companies emerge worldwide. [Read more…]
A Spark Becomes a Surge: How Ryoncil Reignited MSC Development
It’s official: Today marks exactly one year since the cell therapy field celebrated a historic milestone. On December 18, 2024, the FDA granted its first-ever approval for a Mesenchymal Stem Cell (MSC) therapy, Mesoblast’s Ryoncil® (remestemcel‑L‑rknd).
This landmark decision marks not just a regulatory first, but a validation of decades of research into the therapeutic potential of MSCs. Once considered experimental, MSC therapies are now stepping into mainstream medicine, signaling the beginning of a new era in regenerative treatments. The approval has ignited renewed investment, scientific exploration, and clinical interest, setting the stage for rapid growth and broader adoption of MSC-based therapeutic products across multiple disease areas. [Read more…]
Hematopoietic Stem Cells: What Diseases Can these Stem Cells Treat?
Hematopoietic stem cells (HSCs) are defined as stem cells that have a preference for becoming cells of the blood and immune system, such as white blood cells, red blood cells, and platelets. Found in the peripheral blood and bone marrow, hematopoietic stem cells are also present in plentiful supply within the umbilical cord blood of newborn babies.
For the past thirty years, cord blood has been used within transplant medicine, including for the treatment of leukemia and other blood diseases. For most conditions in which a bone marrow or peripheral blood stem cell transplant is an option, a cord blood transplant is a potential alternative.
Hematopoietic Stem Cells
In this article:
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 336
- Next Page »